Search

Your search keyword '"Mönig, S"' showing total 25 results
Start Over Author "Mönig, S" Publication Type Books
25 results on '"Mönig, S"'

14. „Lymph node revealing solution“ beim Magenkarzinom — Bedeutung einer speziellen Aufarbeitungstechnik des Fettgewebes für das Lymphknotenstaging / Lymph Node Revealing Solution in Gastric Carcinoma: Impact of a New Processing Technique of Fat Tissue for Lymph Node Staging

Author

Mönig, S. P., primary, Prenzel, K., additional, Baldus, S. E., additional, Zirbes, T. K., additional, Pham, T. D. C., additional, Dienes, H. P., additional, and Hölscher, A. H., additional

Published
2001
Full Text
View/download PDF

25. ERCC1 Gen-Polymorphismus zur Responseund Prognoseprädiktion einer neoadjuvanten Radiochemotherapie beim Adenocarcinom des Ösophagus.

Author

Metzger, R., Warnecke-Eberz, U., Kütting, F., Alakus, H., Drebber, U., Brabender, J., Vallböhmer, D., Mönig, S., Hölscher, A.H., and Bollschweiler, E.

Abstract

Introduction: Neoadjuvant radiochemotherapy (RT/CTx) regimens were primarily designed for treatment of squamous cell carcinoma (SCC) of the esophagus. Own results demonstrate that also patients with locally advanced adenocarcinoma (AC) of the esophagus may achieve a major response in 30 % with a 3 year survival rate of 80 %. To identify these patients, ERCC1 (rs11615) gene polymorphisms were analyzed. ERCC1 is a key enzyme of the nucleotide excision and repair (NER) complex to prevent DNA inter- and intrastrand crosslinks. Methods: Genomic DNA from 144 patients with adenocarcinoma of the esophagus was extracted from paraffin-embedded tissues. For analysis of ERCC1 single nucleotide polymorphisms (SNPs) allelic discrimination was performed by quantitative realtime PCR. Two allele-specific TaqMan probes in competition were used for amplification of ERCC1 (rs11615). Allelic genotyping was correlated with histomorphologic tumor regression and survival after neoadjuvant RT/CTx. Major response (MaHR) was defined as ≤ 10 % vital residual tumor cells. Results: Analysis of tumor regression revealed a MaHR in 49/144 (34 %) patients with a 5-year survival rate (5-YSR) of 72 % (p = 0.0001). ERCC1 gene polymorphisms for all patients showed the following expression pattern: ERCC1 polymorphism (rs11615) CC: n = 13 (9 %), TT: n = 74 (51 %), CT: n = 57 (40 %). ERCC1 polymorphism CT was identified as a predictor for response to the neoadjuvant RT/CTx (p < 0.001). The 5-YSR for patients with CT genotype was 53 %. Contrary to this, the 5-YSR for the group of patients with a CC/TT-polymorphism decreased to 33 %. Conclusion: Analysis of ERCC1 (rs11615) gene polymorphisms reveals a significant (p < 0.001) correlation with response and survival in patients with adenocarcinoma of the esophagus treated with a neoadjuvant radiochemotherapy (CDDP, 5-FU, 36Gy). Single nucleotide polymorphisms of ERCC1 (rs11615) could therefore be applied to further individualize therapy in esophageal cancer. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results